Grimes & Company, Inc. Regulus Therapeutics Inc. Call Options Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RGLS
# of Institutions
74Shares Held
56.5MCall Options Held
79.3KPut Options Held
20.3K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$21.1 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$10.6 Million0.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$8.2 Million1.15% of portfolio
-
Octagon Capital Advisors LP New York, NY4.26MShares$6.99 Million1.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.09MShares$6.71 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $24M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...